ICO Therapeutics Home

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, moving into Phase 2 for the treatment of DME, iCo-008; a product with Phase 2 clinical history to be developed for severe ocular allergies and age-related macular degeneration; and iCo-009, an oral formulation of Amphotericin B for sight and life-threatening diseases. iCo granted a license option for iCo-008 systemic uses to Immune Pharmaceuticals in December 2010. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration.

iCo was recently awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and is a Canada's Top 10 Competition winner.

iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO".

Latest News Release


iCo Therapeutics Inc. is pleased to announce that Immune Pharmaceuticals (IMMUNE) has licensed Bertilimumab (iCo-008) for systemic uses, pursuant to an option agreement previously announced in December 2010. iCo may receive US $32 million in milestone consideration for the license, plus royalties. iCo retains worldwide exclusive rights to all ocular applications, including a number of sight-threatening diseases.


Upfront consideration includes US $500,000 cash, 600,000 IMMUNE shares and 200,000 IMMUNE warrants. Currently IMMUNE shares are worth US $2 per share.


"We look forward to working with IMMUNE to advance Bertilimumab. IMMUNE has assembled an impressive group of experts and management and we believe the team has the expertise to successfully drive Bertilimumab clinical development," stated Andrew Rae, iCo's President and CEO. "We are pleased to have unlocked the value of Bertilimumab in indications outside of our core ocular focus. iCo remains committed to developing Bertilimumab for vernal keratoconjunctivitis and age-related macular degeneration." According to Professor Marc Rothenberg, Chief Scientific Officer of IMMUNE and the Director of the Division of Allergy and Immunology and the Center for Eosinophilic Diseases at Cincinnati's Children's Hospital, "Bertilimumab has great potential for the treatment of eosinophilic inflammatory bowel diseases (IBD) and eosinophilic gastro-intestinal diseases (EGID). Bertilimumab is the first monoclonal antibody to specifically neutralize human eotaxin-1, a chemokine, associated with inflammatory disease activity in Crohn's Disease and Ulcerative Colitis."


Dr. Daniel Teper, CEO of IMMUNE, commented: "Bertilimumab is the top priority in IMMUNE's growing portfolio of Monoclonal Antibodies. We are initiating the manufacturing of a new GMP batch of Bertilimumab with a leading biologics manufacturer and actively preparing for phase II clinical trials."


About Bertilimumab


Bertilimumab (also known as iCo-008 or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that act as messenger molecules between the cells of the immune system. Bertilimumab has been in 126 patients in Phase 1 and 2 studies, has a good safety profile and has shown evidence of efficacy in a severe allergy indication. Bertilimumab may be indicated for inflammatory disorders including Severe Asthma, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis).


Marc Rothenberg co-authored a paper, (Takeda et al, Nature 2009. "CCR3 is a Target for Age-related Macular Degeneration Diagnosis and Therapy"), indicating that iCo-008, a ligand for CCR3, may be effective in treating wet age related macular degeneration (wAMD). iCo is currently planning exploratory studies for iCo-008 in wAMD and a Phase 2 study in severe ocular allergies (vernal & atopic keratoconjunctivitis). iCo licensed the exclusive world-wide rights to Bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the Global Biologics Unit of AstraZeneca.


About IMMUNE Pharmaceuticals


IMMUNE Pharmaceuticals is an Israel and U.S. based biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing significant unmet medical needs in the treatment of cancer and inflammatory diseases. IMMUNE Pharmaceuticals has built a robust pipeline of clinical and pre-clinical candidates based on novel targets and novel antibody technologies. For more information, visit the Company website at: www.immunepharmaceuticals.com.



Ahead of the HerdAbout Us

Aheadoftheherd.com is a community where investors trade ideas on the buying and selling of stocks.

AheadoftheHerd.com isn't just about hosting stock forums. It's so much, much more! We have twenty-six individual forums ranging from such diverse topics as Government & Politics, Economics, Hobbies and Technology to Humour, Health & Wellness, Business & Finance and Agriculture.

Many of our contributing authors are experts in their respective fields. They are world acclaimed analysts and writers whose reports, assays and articles are relative to our forum topics.


Ahead of the HerdRelated Articles

Two for Diabetes

iCo Therapeutics - Socially Responsible Investing

Ahead of the HerdSponsors List

Alder Resources Ltd
Altair Ventures Inc
Amazon Mining
Canadian Int'l Minerals Inc
Cangold Ltd
Cariboo Rose Resources Ltd
Caza Gold Corp
Donner Metals Ltd
Encanto Potash Corp.
Great Panther Silver Ltd
ICO Therapeutics Inc.
Kootenay Gold Inc.
Mukuba Resources Ltd
Niogold Mining Corp
RiverStone Resources Inc.
Roxgold Inc.
Sernova Corp.
Spanish Mountain Gold Ltd
Talison Lithium
Terraco Gold Corp
Texalta Petroleum Ltd
Tiex Inc.
TNR Gold Corp.
Uranerz Energy Corp.
VMS Ventures Inc.
Western Potash Corp.

Ahead of the HerdOur Location


Office Hours
5am - 4:30pm, M-F
9am - 12pm Saturday

No Charge  Newsletter Signup   Free Forum Signup

To contact us please email rick.mills@aheadoftheherd.com

Ahead of the Herd